Compare
Side by side
Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.
Selected 1 of 3
Comparison
Triptorelin
Reproductive & hormonal
Evidence level
Strong evidence
Approval status
Approved drug
Mechanism of action
- 1.Activates pituitary GnRH receptors, initially increasing then exhausting LH and FSH release.
- 2.Sustained occupancy reduces receptor numbers, so the pituitary stops responding.
- 3.Testosterone or oestradiol falls to castrate or menopausal levels.
- 4.In children, the pubertal hormone signal is removed, halting progression.
- 5.Depot microspheres release the peptide steadily over one, three or six months.
Studied for
- Advanced prostate cancer
- Endometriosis
- Central precocious puberty
- Uterine fibroids
- Downregulation before IVF cycles in some countries
Reported effects
- Castrate testosterone levels within about a month
- Pain and lesion reduction in endometriosis
- Stabilisation or regression of pubertal signs in children
- Reversible bone density loss during treatment
- Initial hormone flare in the first week
Side effects
- Hot flushes
- Loss of libido and erectile dysfunction
- Bone density loss
- Headache and mood change
- Vaginal dryness and bleeding irregularities
- Injection-site reactions
- Tumour flare at the start of treatment
Research protocol
Research context only - prescription medicine. Typical licensed dosing is 3.75 mg intramuscularly every 28 days or 11.25 mg every three months, with paediatric dosing weight-based and adjusted as the child grows; trials track testosterone, pubertal staging or pain scores over 6 to 12 months.
Research context only
Evidence justification
Randomised trials across prostate cancer, endometriosis and central precocious puberty with objective endocrine endpoints, plus widespread regulatory approval.